It is indicated for the treatment of metastatic HER2+ BC in individuals who have not received prior therapy as well as for the neoadjuvant treatment of HER2+ early-stage/locally advanced BC and adjuvant treatment for HER2+ early-stage BC at high risk of recurrence [48]. Here, ERBB2 is linked to breast cancer.